Compare Entegris Inc (ENTG) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Illumina, Inc. — how do they compare? Entegris Inc trades at $162.41 (market cap $24.78B), while Illumina, Inc. trades at $266.42 (market cap $39.95B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Entegris Inc pays a 0.25% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Illumina, Inc. for 83 Days on average.
| ENTG | ILMN | |
|---|---|---|
Market Cap | $24.78B | $39.95B |
Volume | 2,648,320 | 3,169,503 |
Sector | Technology | Health |
52-Week High | $184.00 | $293.69 |
52-Week Low | $68.80 | $91.00 |
Typical Hold Time | 41 Days | 83 Days |
Enterprise Value | $27.99B | $41.31B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $166.32, down 0.34% on the day, with a bullish technical signal and strong institutional backing. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.93 surpassing the $0.822 forecast. Revenue remains stable around $3.2B, while profitability metrics show a net income margin of 9.18%. Recent news highlights robust AI-driven semiconductor demand and successful patent defenses.
The outlook is positive, supported by analyst consensus with a $182.43 price target and 70% buy ratings. Key opportunities include exposure to growing semiconductor complexity and AI investments. Risks involve high valuation multiples, such as a P/E of 81.1, and sensitivity to semiconductor industry cycles.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
